United Therapeutics Corporation (UTHR) — ESG & Values Scores

Environment story

United Therapeutics discloses minimal Scope 1/2 emissions data and provides no comprehensive Scope 3 accounting. The company acknowledges water and electrical power dependency for manufacturing but lacks net-zero targets or decarbonization commitments. Animal testing for regulatory compliance and xenotransplantation research is acknowledged but not quantified. No evidence of verified renewable energy procurement or operational carbon-reduction initiatives. The 10-K emphasizes manufacturing resilience and supply-chain risks but omits ESG reporting frameworks. Greenwashing risk: no climate commitments, no emissions transparency, and heavy reliance on third-party manufacturing with opaque carbon footprints.

Criticisms on file

Undisclosed Scope 1, 2, and 3 emissions; no net-zero target or climate commitments
Source: UTHR 10-K 2025 (Item 1A Risk Factors and MD&A sections); no ESG or sustainability report identified in filings.
Animal testing for regulatory compliance and xenotransplantation research; risk of activist opposition and operational disruption
Source: UTHR 10-K 2025, Item 1A Risk Factors: 'Negative attention from special interest groups may impair our business.'
Hazardous materials handling and environmental compliance risks; disposal of company products by patients outside company control
Source: UTHR 10-K 2025, Item 1A Risk Factors: 'Improper handling of hazardous materials used in our activities could expose us to significant remediation liabilities.'

Disclosed initiatives

Water Quality Risk Mitigation

Company acknowledges dependency on local municipal water supply for manufacturing; notes that water-quality failures could disrupt production of key products.

Risk management focus; no proactive decarbonization or efficiency gains disclosed.
Electrical Grid Reliability Monitoring

Company monitors aging U.S. power grid and data-center-driven demand increases; acknowledges risk of capacity constraints at manufacturing facilities.

Reactive risk awareness; no renewable energy transition or efficiency investments disclosed.

Social story

Limited social transparency in public filings. No disclosed CEO-to-median-worker pay ratio, workforce diversity percentages, or union engagement data. 10-K notes founder/CEO Martine Rothblatt as critical to company strategy but no succession planning or pay-equity disclosures. Supply-chain labor practices, particularly for third-party manufacturers, are not audited or reported. No evidence of formal DEI programs, labor standards for suppliers, or human-rights due diligence. Manufacturing personnel recruitment noted as competitive but no wage/benefits leadership claimed. Litigation exposure from patient-assistance programs and 340B contract pharmacy policies suggests potential harm to patient access and equity.

Criticisms on file

Litigation related to patient assistance programs: Humana Inc., United Healthcare Services, Inc., MSP Recovery Claims Series LLC alleging RICO and state law violations regarding donations to patient-assistance charities
Source: UTHR 10-K 2025, Item 1A Risk Factors and Note 14—Litigation; MD&A section on Legal Compliance.
340B Contract Pharmacy Policy: HRSA threatened enforcement action; company challenged in court; risk of continued litigation and enforcement by OIG or states
Source: UTHR 10-K 2025, Item 1A Risk Factors: 'We may be subject to enforcement action or penalties in connection with the contract pharmacy policy we have implemented pursuant to the 340B program.'
No disclosed DEI commitments, workforce diversity metrics, CEO-to-worker pay ratio, or union relations; supply-chain labor-practice audits not disclosed
Source: UTHR 10-K 2025 (comprehensive search of Item 1—Business, Item 1A—Risk Factors, and MD&A sections; no ESG or diversity report identified).

Disclosed initiatives

Patient Assistance Programs

Company sponsors patient assistance programs for insurance premium and co-pay assistance; subject to DOJ scrutiny and litigation.

Intended to improve access; facing regulatory and reputational risk from enforcement actions and lawsuits (Humana, United Healthcare, MSP Recovery).
Manufacturing Personnel Recruitment

Company notes competition for experienced technical and entry-level operations personnel in biopharmaceutical manufacturing hubs; no wage leadership or retention programs disclosed.

Hiring challenges acknowledged; no proactive workforce development or equity initiatives disclosed.
United Therapeutics Cares Patient Relations Program

Recently launched program increasing company access to sensitive patient information.

Intended to improve patient engagement; introduces data privacy and security risks if not managed robustly.

Governance story

Governance structure exhibits mixed risk profile. Delaware Public Benefit Corporation (PBC) status since 2021 introduces potential conflict between shareholder value maximization and stakeholder interests; board must balance financial returns against public-benefit obligations, potentially limiting takeover attractiveness. No evidence of dual-class voting structure disclosed; board independence percentage not reported. Significant litigation exposure: ongoing disputes with Sandoz ($74.1 million accrual for settlement violations), Liquidia (patent infringement claims), Humana/United Healthcare (patient-assistance programs), and 340B contract pharmacy policy enforcement threats. FTC antitrust scrutiny of generic settlement agreements noted. Lobbying expenditures not disclosed in 10-K; no active climate or consumer-protection deregulation campaigns identified but regulatory compliance risk is substantial. No conflicts-of-interest or board-diversity disclosures in source documents.

Criticisms on file

Sandoz Settlement Agreement Litigation: $74.1 million accrual for judgment and post-judgment interest; Sandoz claims company violated settlement terms; ultimate liability may exceed current accrual.
Source: UTHR 10-K 2025, Item 1A Risk Factors ('Third parties have challenged, and may in the future challenge, the validity of our patents...') and Note 14—Litigation (not provided in source documents but referenced in MD&A).
Liquidia Patent Infringement Litigation: Liquidia filed April 2025 lawsuit alleging Tyvaso DPI infringes Liquidia patent; company states it has 'meritorious defenses' but acknowledges litigation risk and potential substantial damages.
Source: UTHR 10-K 2025, Item 1A Risk Factors: 'In April 2025, Liquidia initiated litigation against us alleging that Tyvaso DPI infringes a patent assigned to Liquidia.'
FTC Antitrust Scrutiny: Company entered settlement agreements with generic competitors; acknowledges FTC has challenged similar agreements; exposure to future antitrust claims.
Source: UTHR 10-K 2025, Item 1A Risk Factors: 'In some instances, the FTC has brought actions against brand and generic companies that have entered into such agreements, alleging that they violate antitrust laws.'
HRSA 340B Contract Pharmacy Policy Enforcement Threats: HRSA threatened enforcement action and referred matter to OIG; company won favorable court ruling in November 2021 (affirmed on appeal September 2024); ongoing litigation risk and potential state-level enforcement.
Source: UTHR 10-K 2025, Item 1A Risk Factors: 'We may be subject to enforcement action or penalties in connection with the contract pharmacy policy we have implemented pursuant to the 340B program.'
Humana/United Healthcare Patient Assistance Program Litigation: Company sued for RICO and state law violations related to patient-assistance charity donations; DOJ has previously taken enforcement action against pharmaceutical companies on similar issues.
Source: UTHR 10-K 2025, Item 1A Risk Factors: 'Patient assistance programs for pharmaceutical products have come under increasing scrutiny...'; Note 14—Litigation (referenced but not detailed in source documents).
No board independence percentage, chair/CEO separation, or diversity disclosures in 10-K; governance transparency limited.
Source: UTHR 10-K 2025 (comprehensive search; no proxy statement or governance details provided in source documents).

Disclosed initiatives

Public Benefit Corporation Governance Framework

Company converted to Delaware PBC in 2021; board required to balance shareholder financial interests with stakeholder interests and public-benefit purpose.

Structural commitment to broader stakeholder consideration; may limit shareholder value maximization in M&A scenarios; creates complexity in governance decision-making.
Unsecured Revolving Credit Facility

In April 2025, company entered into $2.5 billion unsecured revolving credit facility (2025 Credit Agreement) with 5-year maturity (2030); zero outstanding balance as of December 31, 2025.

Provides financial flexibility; demonstrates disciplined capital management and low leverage.
Exclusive Forum Bylaw

Company bylaws designate Delaware Court of Chancery as exclusive forum for internal corporate claims and federal courts for Securities Act claims.

Limits shareholder litigation options; may deter certain types of shareholder claims.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of United Therapeutics Corporation. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open United Therapeutics Corporation in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)